CN117323362A - 一种抗幽门螺杆菌的植物挥发油组合物 - Google Patents
一种抗幽门螺杆菌的植物挥发油组合物 Download PDFInfo
- Publication number
- CN117323362A CN117323362A CN202311419138.0A CN202311419138A CN117323362A CN 117323362 A CN117323362 A CN 117323362A CN 202311419138 A CN202311419138 A CN 202311419138A CN 117323362 A CN117323362 A CN 117323362A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- volume percentage
- essential oil
- cinnamon
- patchouli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 246
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 52
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 50
- 241000196324 Embryophyta Species 0.000 claims abstract description 46
- 240000002505 Pogostemon cablin Species 0.000 claims abstract description 46
- 235000011751 Pogostemon cablin Nutrition 0.000 claims abstract description 45
- 240000007673 Origanum vulgare Species 0.000 claims abstract description 36
- 235000010677 Origanum vulgare Nutrition 0.000 claims abstract description 10
- 210000001156 gastric mucosa Anatomy 0.000 claims abstract description 7
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract 12
- 239000003814 drug Substances 0.000 claims description 31
- 235000013628 Lantana involucrata Nutrition 0.000 claims description 26
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims description 26
- 241001529744 Origanum Species 0.000 claims description 24
- 235000011203 Origanum Nutrition 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 9
- 208000007882 Gastritis Diseases 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 5
- 208000000718 duodenal ulcer Diseases 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000000606 toothpaste Substances 0.000 claims description 4
- 229940034610 toothpaste Drugs 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000004530 micro-emulsion Substances 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 239000003205 fragrance Substances 0.000 abstract description 2
- 230000005802 health problem Effects 0.000 abstract description 2
- 241000723347 Cinnamomum Species 0.000 description 38
- 239000000463 material Substances 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 230000002496 gastric effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 102000004890 Interleukin-8 Human genes 0.000 description 9
- 108090001007 Interleukin-8 Proteins 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241001529821 Agastache Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 4
- 108010046334 Urease Proteins 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 4
- 229960002626 clarithromycin Drugs 0.000 description 4
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960000381 omeprazole Drugs 0.000 description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- -1 antiseptic Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 238000013115 immunohistochemical detection Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 240000003553 Leptospermum scoparium Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940127022 high-dose drug Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229940127021 low-dose drug Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000001738 pogostemon cablin oil Substances 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241001252601 Blumea Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241001643642 Viticis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000006781 columbia blood agar Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 108010038415 interleukin-8 receptors Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种抗幽门螺杆菌的植物挥发油组合物,所述的植物挥发油组合物包含牛至挥发油、肉桂挥发油和广藿香挥发油,所述的牛至挥发油体积百分数为16.67%~50%,所述的肉桂挥发油体积百分数为16.67%~50%,所述的广藿香挥发油体积百分数为16.67%~50%。本发明制备的植物挥发油组合物具有良好的抗幽门螺杆菌和胃粘膜保护作用,安全性高,香味适宜等特点,为预防或治疗幽门螺杆菌导致的疾病或健康问题提供了新的技术方案。
Description
技术领域
本发明涉及一种抗幽门螺杆菌的植物挥发油组合物,具体涉及一种将牛至挥发油、肉桂挥发油、广藿香挥发油三种植物挥发油按不同比例组合后得到能够协同增效,抑制幽门螺杆菌的组合物,属于医药技术领域。
背景技术
植物挥发油属于植物次生代谢产物,具有抗氧化、抗病毒、抗菌、抗癌、提高免疫力等多种生物学活性,现代药理研究还表明植物挥发油还具有抗炎、抗过敏的作用。目前植物挥发油多用于食品行业,因为其毒副作用低的优点,通常用作食品添加剂达到防腐的作用。《中华人民共和国药典(2020版)》第一部收载有丁香罗勒油、八角茴香油、广藿香油、牡荆油等十余种植物挥发油,都对应有相应的测定方法及质量标准,植物挥发油在食品、医药、畜牧业领域的应用正在逐步受到关注。
幽门螺杆菌(Helicobacter Pylori,HP)是一种微需氧的革兰氏阴性菌,可定植于人胃上皮粘膜,为胃炎、胃溃疡的常见病因之一。2015年全球约有44亿人感染幽门螺杆菌。尽管随着公共卫生情况改善和社会经济的发展幽门螺杆菌感染率有所降低,但幽门螺杆菌仍然是最常见的人类细菌病原体,且90%的恶性胃肿瘤与幽门螺杆菌感染有关。因此,2017年世界卫生组织将幽门螺杆菌列为一类致癌物质。
研究表明几乎所有的幽门螺杆菌感染者未经抗菌治疗最后都会发展成慢性胃炎,但是绝大多数在初期无表现症状,后期会产生嗳气、口臭、胀气等症状;10%-15%的患者会发展为十二指肠溃疡表型,会有1%-3%的感染者发展为胃癌,仅有0.1%的感染者会产生胃粘膜组织淋巴瘤;大约90%-100%的十二指肠溃疡和70%-80%的胃溃疡是由幽门螺杆菌引起的。幽门螺杆菌进入口腔后借助鞭毛移动至胃幽门处,在幽门处定植后产生的尿素酶将尿素分解产生氨和碳酸氢根离子。碳酸氢根离子会中和胃酸,使得胃液pH上升,使幽门螺杆菌可在此处定植生存,而氨也会辅助碳酸氢根离子形成碱性保护层,保护幽门螺杆菌免受胃酸腐蚀,二者使人产生口臭、嗳气、胃痛、积食等症状。口腔类抑制幽门螺杆菌产品可以使幽门螺杆菌进入胃中定植的概率降低;清除胃中定植的幽门螺杆菌可以有效降低幽门螺杆菌导致的胃炎、胃溃疡、十二指肠溃疡的发生概率,也可以有效保护胃粘膜。
中国专利CN111617021A公开了一种茶树挥发油与丁香油合用抗幽门螺杆菌的方法,保护了茶树挥发油及其抗幽门螺杆菌的作用,配方中添加大量辅料,存在安全隐患;中国专利CN112206180A公开了一种抗幽门螺杆菌口腔护理产品的制备方法,保护了一种抗幽门螺杆菌植物复配挥发油(薄荷素油、艾叶油、沙棘油、甜橙油、绿茶油、薰衣草油等任选三种复配)的护理产品及其制备方法;中国专利CN110075036A公开了一种抗幽门螺杆菌的药物牙膏材料及制备方法,保护了薄荷精油与金银花提取物,黄连提取物,鱼腥草提取物联合使用抑制幽门螺杆菌,作为牙膏原料预防胃病发生的作用。口腔日化产品没有从根源解决幽门螺杆菌定植的问题,无法清除幽门螺杆菌诱导的胃部疾病。
发明内容
本发明的目的是获得安全性高、疗效好的植物挥发油组合物,为预防或治疗幽门螺杆菌导致的疾病或健康问题提供新的技术方案和选择。
实现本发明技术目的采用的技术方案是:
一种抗幽门螺杆菌的植物挥发油组合物,所述的植物挥发油组合物包含牛至挥发油、肉桂挥发油和广藿香挥发油,所述的牛至挥发油体积百分数为16.67%~50%,所述的肉桂挥发油体积百分数为16.67%~50%,所述的广藿香挥发油体积百分数为16.67%~50%。
优选的,所述的牛至挥发油体积百分数为33.34%,所述的肉桂挥发油体积百分数为33.33%,所述的广藿香挥发油体积百分数为33.33%,即牛至挥发油:肉桂挥发油:广藿香挥发油的体积比为1:1:1。
优选的,所述的牛至挥发油体积百分数为16.67%,所述的肉桂挥发油体积百分数为33.33%,所述的广藿香挥发油体积百分数为50%,即牛至挥发油:肉桂挥发油:广藿香挥发油的体积比为1:2:3。
优选的,所述的牛至挥发油体积百分数为50%,所述的肉桂挥发油体积百分数为16.67%,所述的广藿香挥发油体积百分数为33.33%,即牛至挥发油:肉桂挥发油:广藿香挥发油的体积比为3:1:2。
一种植物挥发油组合物在制备抗幽门螺杆菌功能性产品中的应用,所述的植物挥发油组合物包含牛至挥发油、肉桂挥发油和广藿香挥发油,所述牛至挥发油体积百分数为16.67%~50%,所述肉桂挥发油体积百分数为16.67%~50%,所述广藿香挥发油体积百分数为16.67%~50%;所述的功能性产品包含药品、保健食品或口腔护理日化产品。
优选的,所述的牛至挥发油体积百分数为33.34%,所述的肉桂挥发油体积百分数为33.33%,所述的广藿香挥发油体积百分数为33.33%;
优选的,所述的牛至挥发油体积百分数为16.67%,所述的肉桂挥发油体积百分数为
33.33%,所述的广藿香挥发油体积百分数为50%;
优选的,所述的牛至挥发油体积百分数为50%,所述的肉桂挥发油体积百分数为16.67%,
所述的广藿香挥发油体积百分数为33.33%。
进一步的,所述的植物挥发油组合物在制备抗胃炎、胃溃疡、十二指肠溃疡药品中的应用。
进一步的,所述的植物挥发油组合物在制备对胃粘膜有辅助保护功能的保健食品中的应用。
进一步的,所述的植物挥发油组合物在制备对口腔幽门螺杆菌有抑制功能的口腔护理日化产品中的应用。
进一步的,所述的功能性产品包含治疗有效量的植物挥发油组合物,还包含药学上、保健食品或口腔护理产品可接受的载体或辅料。药物、保健食品或口腔护理产品中植物挥发油组合物的治疗有效量可为药物的规格,也可根据给药量使用多个单位制剂。
进一步的,所述的功能性产品的剂型为滴丸、软胶囊、微乳、微囊、微球、脂质体、牙膏或漱口水中的一种或几种。
在本发明中的牛至挥发油为唇形科牛至Origanum vulgare L.的全草所提;肉桂挥发油为樟科植物肉桂Cinnamomum cassiaPresl的干燥树皮所提;广藿香挥发油为唇形科植物广藿香Pogostemon cablin(Blanco)Benth.的全草所提,且3种药材符合《中华人民共和国药典(2020版)》的标准或现行相关质量标准。本发明所制备的植物挥发油组合物为淡黄色的澄清油状液体,气味芳香,pH为3.7-5.4,呈弱酸性。本发明中所述的牛至挥发油、肉桂挥发油和广藿香挥发油的提取药材应符合《中华人民共和国药典(2020版)》第一部“广藿香”和“肉桂”项下及《中华人民共和国药典(1977版)》第一部“牛至”项下规定或现行相关质量标准。广藿香挥发油也可购买符合《中华人民共和国药典(2020版)》第一部“广藿香油”项下规定的产品。
本领域技术人员可以根据实际需要按照常规方法将制剂规格量的挥发油组合物与药学上、保健食品或口腔护理产品可接受的载体或辅料组合制成本发明所述的剂型。上述可接受的载体或辅料包括:水溶性基质、非水溶性基质、增塑剂、软胶囊剂添加胶料、防腐剂、遮光剂、色素、芳香剂等。本领域技术人员可认识到,某些可接受的赋形剂可提供不止一种功能,并提供可供选择的功能,这取决于制剂中存在多少该赋形剂和制剂中存在哪些其他赋形剂。滴丸加入聚乙二醇类、硬脂酸钠、甘油明胶、聚氧乙烯单硬脂酸酯、聚醚等水溶性基质或硬脂酸、单硬脂酸甘油酯、蜂蜡、虫蜡等非水溶性基质;软胶囊剂添加胶料(明胶)、增塑剂(甘油、山梨醇或二者的混合物)、附加剂(防腐剂、遮光剂、色素、芳香剂)及水等制成;微乳剂型常添加油相、乳化剂、助乳化剂、稳定剂等辅料;微囊与微球剂型选择天然高分子(明胶、阿拉伯胶、海藻酸盐、壳聚糖)或半合成高分子(羧甲基纤维素盐、醋酸纤维素钛酸酯、乙基纤维素、甲基纤维素)辅料作为囊材;脂质体通过添加磷脂类和胆固醇类辅料作为膜材。
技术人员掌握本领域的知识和技能,以使他们能选择用于本发明的适当量的合适的药学上可接受的药用辅料。此外,存在大量技术人员可获得的资源,他们描述药学上可接受的赋形剂,并用于选择合适的药学上可接受的药用辅料(即赋形剂)。实例包括Remington's Pharmaceutical Sciences(Mack Publishing Company),The Hand book ofPharmaceutical Additives(Gower Publishing Limited),and The Hand book ofPharmaceutical Excipients(the American Pharmaceutical Association and thePharmaceutical Press)。
本发明有效抗幽门螺杆菌的三元植物挥发油组合物挥发油成分为牛至挥发油、肉桂挥发油和广藿香挥发油,配制植物挥发油组合物的比例以挥发油体积比计算。
本发明还提供了一种抗幽门螺杆菌的植物挥发油组合物的其制备方法,其包括如下步骤:
(1)牛至挥发油的提取:取200g牛至饮片,加10倍药材重量的纯化水和几颗玻璃珠(直径约4mm),冷凝回流提取6h,收集挥发油提取器上层牛至挥发油。
(2)肉桂挥发油的提取:取200g肉桂饮片,加10倍药材重量的纯化水和几颗玻璃珠(直径约4mm),冷凝回流提取6h,收集挥发油提取器下层肉桂挥发油。
(3)广藿香挥发油的提取:取200g广藿香饮片,加10倍药材重量的纯化水和几颗玻璃珠(直径约4mm),冷凝回流提取6h,收集挥发油提取器上层广藿香挥发油。
(4)按体积百分数计吸取牛至挥发油、肉桂挥发油和广藿香挥发油并混合均匀,牛至挥发油体积百分数为16.67%~50%,肉桂挥发油体积百分数为16.67%~50%,广藿香挥发油体积百分数为16.67%~50%。
术语定义和说明
术语“有效量”或者“治疗有效量”是指足以实现预期应用(包括但不限于如下定义的疾病治疗)的本发明所述植物挥发油组合物的量。治疗有效量可以取决于以下因素而改变:预期应用(体外或者体内),或者所治疗的受试者和疾病病症如受试者的体重和年龄、疾病病症的严重性和给药方式等,其可以由本领域普通技术人员容易地确定。具体剂量将取决于以下因素而改变:所选择的挥发油组合物、所依据的给药方案、是否与其它化合物组合给药、给药的时间安排、所给药的组织和所承载的物理递送系统。
术语“规格”系指每一支、片或其他每一个单位制剂中含有主药的重量(或效价)或含量(%)或装量。在本发明中主药即为植物挥发油组合物。
除非另有说明,本发明使用的所有技术术语和科学术语具有要求保护主题所属领域的标准含义。倘若对于某术语存在多个定义,则以本发明定义为准。
除非另有说明,本发明采用提取方法、抑菌实验或药理检测为本领域常规方法,各步骤和条件可参照本领域常规的操作步骤和条件。
本发明与现有技术相比,具有如下有益效果:
1.本发明牛至挥发油、肉桂挥发油和广藿香挥发油组合而成的植物挥发油组合物相比各单一挥发油、两两组合具有更好的抗幽门螺杆菌的效果,具有协同作用。
2.本发明植物挥发油组合物全部来源于中药挥发油,具有安全性高的优势,且疗效与四联法化学药效果相当。
3.本发明植物挥发油组合物在动物实验中的药效结果表明可以全部替代或部分替代四联法化学药,可达到安全、有效的目的。
4.本发明植物挥发油组合物可以减轻幽门螺杆菌对胃酸的影响,对胃粘膜具有保护作用。
5.本发明植物挥发油组合物具有良好的香味,易于接受。三种挥发油组合后,气味比单方挥发油清新,更易于接受,在使用时可降低由于浓烈气味带来的不适感。
附图说明
图1为各组免疫组化检测IL-8受体定量分析图。
图2为空白对照组胃组织H&E染色切片图。
图3为模型对照组胃组织H&E染色切片图。
图4为低剂量给药组胃组织H&E染色切片图。
图5为高剂量给药组胃组织H&E染色切片图。
图6为联合用药组胃组织H&E染色切片图。
图7为阳性药组胃组织H&E染色切片图。
具体实施方式
实施例1
牛至挥发油的提取:取200g牛至饮片,加10倍药材重量的纯化水和几颗玻璃珠(直径约4mm),冷凝回流提取6h,收集挥发油提取器上层牛至挥发油。
实施例2
肉桂挥发油的提取:取200g肉桂饮片,加10倍药材重量的纯化水和几颗玻璃珠(直径约4mm),冷凝回流提取6h,收集挥发油提取器下层肉桂挥发油。
实施例3
广藿香挥发油的提取:取200g广藿香饮片,加10倍药材重量的纯化水和几颗玻璃珠(直径约4mm),冷凝回流提取6h,收集挥发油提取器上层广藿香挥发油。
实施例4
牛至挥发油33.33%,肉桂挥发油33.33%,广藿香挥发油33.34%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油(1∶1∶1)的复配挥发油4。
实施例5
牛至挥发油16.67%,肉桂挥发油33.33%,广藿香挥发油50%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油(1∶2∶3)的复配挥发油5。
实施例6
牛至挥发油16.67%,肉桂挥发油50%,广藿香挥发油33.33%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油(1∶3∶2)的复配挥发油6。
实施例7
牛至挥发油33.33%,肉桂挥发油16.67%,广藿香挥发油50%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油(2∶1∶3)的复配挥发油7。
实施例8
牛至挥发油33.33%,肉桂挥发油50%,广藿香挥发油16.67%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油(2∶3∶1)的复配挥发油8。
实施例9
牛至挥发油50%,肉桂挥发油16.67%,广藿香挥发油33.33%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油(3∶1∶2)的复配挥发油9。
实施例10
牛至挥发油50%,肉桂挥发油33.33%,广藿香挥发油16.67%,均为体积百分比,配制成牛至挥发油-肉桂挥发油--广藿香挥发油(3∶2∶1)的复配挥发油10。
实施例11各实施例等倍稀释法测抑菌率实验。
幽门螺杆菌菌种购于宁波明舟生物科技有限公司,菌种编号为B84182。试验前一天扩大培养幽门螺杆菌,使其在对数期受试。固体平板选用哥伦比亚血琼脂基础,高温高压灭菌后添加5%的脱纤维羊血后倒平板凝固备用。液体培养基选用脑心培养基,高温高压灭菌后备用。
将菌种接种于培养基,在37℃、微需氧环境中培养。将牛至挥发油、肉桂挥发油、广藿香挥发油以及按不同种类、不同体积比例混合得到的混合挥发油与无水乙醇以体积比1:1混溶。吸取混溶液体,加液体培养基稀释,每组配制为含挥发油或混合挥发油为4μL/mL、2μL/mL、1μL/mL、0.5μL/mL、0.25μL/mL、0.125μL/mL、0.0625μL/mL、0.0313μL/mL浓度梯度中的6个浓度梯度的不含菌培养基。将处于对数生长期的幽门螺杆菌按一定比例稀释后在紫外分光光度计下测定,当吸光度A=1.0时,菌浓度为1×108CFU/mL。调整菌液比例,使每1mL有菌挥发油培养基中菌液浓度为1×105CFU/mL。将每个梯度的有菌含药培养基接种于96孔板,每个孔200μL,每个梯度5个复孔,同时设置阴性对照孔5个,生长对照孔5个。微需氧环境培养72h后用酶标仪在600nm下测量光密度(optical density,OD)值。
计算后将数据用GraphPad Prism.8进行统计学分析。通常认为当抑菌率达到90%时有抑菌效果,抑菌率达到90%时所添加药物的最小浓度为最小抑菌浓度(MIC)。联合抑菌指数(Fractional Inhibitory Concentration Index,FIC)可以用来判断不同抗菌药物之间的相互作用,其计算公式如下。
一般认为当FIC小于0.5时,联合的药物具有协同作用;当FIC为0.5-1时,联合的药物具有相加作用;但是当FIC趋近0.5左右可认为有部分协同作用(吴金勇.牛至和鱼腥草精油联合抑菌作用研究[D].四川农业大学,2022.);当FIC大于1且小于2时,联合的药物具有无关作用;当FIC大于2时,联合的药物具有拮抗作用(《抗菌药物临床合理应用》王爱霞主编,97页)。相加作用是指两种药物联用的效应等于单用各药双倍剂量的效应。
根据表1结果所示,部分配比的组合物都有较好的抗幽门螺杆菌作用,实施例9的复配比例具有较好的协同作用。某些实施例复配后虽然为相加作用,但复配后气味和味道与单方挥发油相比更易于接受。
表1各实施例的最小抑菌浓度及联合抑菌作用结果
实验例12动物实验
选用SPF级Babl/c雄性小鼠22只,购自河南斯克贝斯生物科技股份有限公司(许可证号:SCXK[豫]2020-0005),20g±2g,7~8周龄。分为空白对照组,模型对照组,低剂量药物组,高剂量药物组,联合用药组,阳性药组(四联疗法),空白对照组和模型对照组每组5只,其余每组3只,适应性喂养7天后实验。动物实验分组、给药信息如下:
空白对照组:0.2mL/20g,0.5%CMC-Na(羧甲基纤维素钠)早晚两次灌胃;
模型对照组:0.2mL/20g,0.5%CMC-Na早晚两次灌胃;
低剂量药物组:给药剂量为每次5mg/20g,将实验例9制备的挥发油组合物用0.5%CMC-Na配制为浓度为25mg/mL的混悬液,给药量为0.2mL/20g,早晚两次灌胃给药;
高剂量药物组:给药剂量为每次10mg/20g,将实验例9制备的挥发油组合物用0.5%CMC-Na配制为浓度为50mg/mL的混悬液,给药量为0.2mL/20g,早晚两次灌胃给药;
联合用药组:称取奥美拉唑胶囊(内容物)、克拉霉素片、阿莫西林胶囊(内容物)、枸橼酸铋钾片适量,用0.5%CMC-Na配制为每mL含奥美拉唑0.26mg,克拉霉素6.5mg,阿莫西林13mg和枸橼酸铋钾2.86mg的混合药液,给药量为0.2mL/20g,于早上灌胃给药一次;将实验例9制备的挥发油组合物用0.5%CMC-Na配制为浓度为50mg/mL的混悬液,给药量为0.2mL/20g,于晚上灌胃给药一次。
阳性药组(四联疗法):称取奥美拉唑胶囊(内容物)、克拉霉素片、阿莫西林胶囊(内容物)、橼酸铋钾片适量,用0.5%CMC-Na配制为每mL含奥美拉唑0.26mg,克拉霉素6.5mg,阿莫西林13mg和枸橼酸铋钾2.86mg的混合药液,给药量为0.2mL/20g,早晚两次灌胃。四联疗法作为一种幽门螺杆菌根除疗法,在现在的临床实践中仍然是一种常用的治疗方法,但是四联疗法的用药里含有大量抗生素,可能会引起患者过敏或者是肠道的菌群紊乱,以及细菌耐药性等问题,还有部分患者可能会出现恶心、呕吐等不良反应。
实验第1-14天进行造模,每只小鼠空腹灌胃0.3mL的浓度为1×109CFU/mL的幽门螺杆菌,每两天灌胃一次,连续操作7次。第15-44天,定植处理,正常饲养小鼠让幽门螺杆菌在胃中定植。定植结束后随机取两只空白对照组小鼠,两只造模小鼠取血检测血清IL-8,当模型小鼠血清IL-8明显升高则表明造模成功,用于分组和后续给药。第45-58天连续给药14天,早晚各一次。给药结束48h后,处死小鼠,取血清及胃液和胃体,剪下胃幽门处一小块组织进行快速脲酶检测,结果见表2;测量胃液pH值,结果见表3;小鼠血清用Elisa法检测血清中IL-8和TNF-α含量,结果见表4;取胃组织进行H&E染色及免疫组化检测,免疫组化结果见附图1,H&E染色结果见附图2-7。
表2显示与模型组相比,低剂量组、高剂量组、联合用药组都可有效清除胃中定植的幽门螺杆菌,其中联合用药组清除效果最好,高剂量组次之。动物实验结果可见,服用植物挥发油组合物的小鼠胃中幽门螺杆菌清除效果较好,可以有效阻止幽门螺杆菌诱导的相关疾病的深入发展。
表2各组快速脲酶检测结果
表3显示与空白组相比,模型组小鼠胃液pH明显升高;低剂量组、高剂量组、联合用药组、阳性组小鼠胃液pH均低于模型组,联合用药组效果最佳(P<0.001),低、高剂量组效果次之(P<0.05);表中*表示各组与空白对照组的显著差异,#表示各组与模型对照组的显著差异。幽门螺杆菌通过产生的尿素酶会将营养物质中尿素分解产生氨和碳酸氢根离子,使得环境pH上升,形成碱性保护层使幽门螺杆菌更好的定植,酸性的药物能破坏幽门螺杆菌的碱性保护层,更有利于抑菌作用的发挥。结合动物实验结果,弱酸性药物不仅有助于清除幽门螺杆菌定植,用药后胃液pH升高这一病理特征也能得到较好的缓解。
表3各组小鼠胃液pH的变化。
采用酶联免疫法检测小鼠血清中IL-8和TNF-α含量。当幽门螺杆菌定植于胃中时,会诱导胃中相关受体释放IL-8炎症因子,同时幽门螺杆菌导致的胃炎会产生炎症因子TNF-α,故选用这两个炎症因子来表示相关胃炎治疗情况。结果见表4,低剂量组、高剂量组及联合用药组均可降低小鼠血清IL-8水平(P<0.01),高剂量组小鼠血清中IL-8水平最低(P<0.01),联合用药组次之(P<0.05);低剂量组、高剂量组及联合用药组均可降低小鼠血清IL-8水平(P<0.01);表中*表示各组与空白对照组的显著差异,#表示各组与模型对照组的显著差异。
表4各组小鼠血清IL-8及TNF-α的变化
胃组织H&E染色结果表明,模型组胃粘膜内局部胃底腺排列紊乱,粘膜上皮细胞脱落,粘膜下层水肿,间隙显著增大,见附图3;经实验例9制备的挥发油组合物给药治疗后,可观察到组织结构紊乱情况相比模型对照组有明显改善,炎性细胞浸润情况相比模型对照组明显好转,见附图4~6。
上述各项实验结果说明实验例9制备的挥发油组合物具有良好的体外抗幽门螺杆菌效果,体内动物实验也同样表明本发明的植物挥发油组合物能有效清除胃中定植的幽门螺杆菌,治疗幽门螺杆菌所造成的相关胃炎。
实施例13
随机挑选十位同学闻及口尝本发明的对比例及实施例所制备的挥发油和挥发油组合物,感官评价如表5所示。
表5各对比例及实施例的感官评价表
观察表5得,大多数人对广藿香挥发油及含广藿香油比例较高的组合物接受程度较低,因为广藿香挥发油有较强烈的刺激的味道且口尝辛辣微苦;牛至挥发油接受程度较高,部分人认为其有芳香气味,不可接受者认为其刺激性较大;肉桂挥发油接受程度最高,因为其嗅之芬芳且口尝微甜,肉桂为常见药食两用食材,人们接受度较高。总体观察来看,复配后的挥发油接受程度都较高,气味和口尝味道都较单方有所改善。
对比例
对比例1
牛至挥发油100μL
对比例2
肉桂挥发油100μL
对比例3
广藿香挥发油100μL
对比例4
肉桂挥发油50%,广藿香挥发油50%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油(0∶1∶1)的复配挥发油1。
对比例5
牛至挥发油50%,广藿香挥发油50%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油(1∶0∶1)的复配挥发油2。
对比例6
牛至挥发油50%,肉桂挥发油50%,均为体积百分比,配制成牛至挥发油-肉桂挥发油-广藿香挥发油为(1∶1∶0)的复配挥发油3。
采用IBM SPSS Statistics 26对数据进行处理,在GraphPad Prism 8及AI中将数据可视化,数据以Mean±SD表示,两组间采用单因素t检验进行数据统计分析,P<0.05被认为有统计学意义。与空白组比较,*:P<0.05,****:P<0.0001;与模型组比较,#:P<0.05,##:P<0.01,###:P<0.001。
Claims (10)
1.一种抗幽门螺杆菌的植物挥发油组合物,其特征在于,所述的植物挥发油组合物包含牛至挥发油、肉桂挥发油和广藿香挥发油,所述的牛至挥发油体积百分数为16.67%~50%,所述的肉桂挥发油体积百分数为16.67%~50%,所述的广藿香挥发油体积百分数为16.67%~50%。
2.根据权利要求1所述的植物挥发油组合物,其特征在于,所述的牛至挥发油体积百分数为33.34%,所述的肉桂挥发油体积百分数为33.33%,所述的广藿香挥发油体积百分数为33.33%。
3.根据权利要求1所述的植物挥发油组合物,其特征在于,所述的牛至挥发油体积百分数为16.67%,所述的肉桂挥发油体积百分数为33.33%,所述的广藿香挥发油体积百分数为50%。
4.根据权利要求1所述的植物挥发油组合物,其特征在于,所述的牛至挥发油体积百分数为50%,所述的肉桂挥发油体积百分数为16.67%,所述的广藿香挥发油体积百分数为33.33%。
5.一种如权利要求1所述的植物挥发油组合物在制备抗幽门螺杆菌功能性产品中的应用,所述的植物挥发油组合物包含牛至挥发油、肉桂挥发油和广藿香挥发油,所述的牛至挥发油体积百分数为16.67%~50%,所述的肉桂挥发油体积百分数为16.67%~50%,所述的广藿香挥发油体积百分数为16.67%~50%;
所述的功能性产品包含药品、保健食品或口腔护理日化产品。
6.根据权利要求5所述的植物挥发油组合物的应用,其特征在于,所述的牛至挥发油体积百分数为33.34%,所述的肉桂挥发油体积百分数为33.33%,所述的广藿香挥发油体积百分数为33.33%;
或所述的牛至挥发油体积百分数为16.67%,所述的肉桂挥发油体积百分数为33.33%,
所述的广藿香挥发油体积百分数为50%;
或所述的牛至挥发油体积百分数为50%,所述的肉桂挥发油体积百分数为16.67%,所述的广藿香挥发油体积百分数为33.33%。
7.根据权利要求5所述的植物挥发油组合物的应用,其特征在于,所述的植物挥发油组合物在制备抗胃炎、胃溃疡、十二指肠溃疡药品中的应用。
8.根据权利要求5所述的植物挥发油组合物的应用,其特征在于,所述的植物挥发油组合物在制备对胃粘膜有辅助保护功能的保健食品中或对口腔幽门螺杆菌有抑制功能的口腔护理日化产品中的应用。
9.根据权利要求5所述的植物挥发油组合物的应用,其特征在于,所述的功能性产品包含治疗有效量的植物挥发油组合物,还包含药学上、保健食品或口腔护理产品可接受的载体或辅料。
10.根据权利要求5所述的植物挥发油组合物的应用,其特征在于,所述的功能性产品的剂型为滴丸、软胶囊、微乳、微囊、微球、脂质体、牙膏或漱口水。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311419138.0A CN117323362A (zh) | 2023-10-30 | 2023-10-30 | 一种抗幽门螺杆菌的植物挥发油组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311419138.0A CN117323362A (zh) | 2023-10-30 | 2023-10-30 | 一种抗幽门螺杆菌的植物挥发油组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117323362A true CN117323362A (zh) | 2024-01-02 |
Family
ID=89295411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311419138.0A Pending CN117323362A (zh) | 2023-10-30 | 2023-10-30 | 一种抗幽门螺杆菌的植物挥发油组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117323362A (zh) |
-
2023
- 2023-10-30 CN CN202311419138.0A patent/CN117323362A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8597690B2 (en) | Pharmaceutical composition | |
CN101559092B (zh) | 一种杜仲提取物的应用 | |
CN104547826B (zh) | 高良姜提取物治疗痛经的医药用途 | |
CN102274314A (zh) | 常青球虫散及其制备方法 | |
CN107427697A (zh) | 在非人动物中治疗腹泻和促进肠道健康的方法 | |
CN101744924B (zh) | 大菱鲆细菌性疾病的中草药复方 | |
CN101579392A (zh) | 一种金银花叶有效部位药物组合物及其制备方法 | |
CN107106536A (zh) | 治疗伴侣动物的腹泻的方法 | |
CN112516205A (zh) | 一种治疗幽门螺杆菌感染的中药组合物 | |
CN102198195A (zh) | 一种具有抗氧化功能的药物组合物 | |
Kumari et al. | Study on the immuno-modulatory effect of herbal extract of Asparagus racemosus Willd. in broiler chicks | |
CN114470042B (zh) | 一种防治动物肝损伤的组合物及其制备方法和用途 | |
KR101373770B1 (ko) | 백지 추출물을 유효성분으로 함유하는 장출혈성 대장균 감염증의 예방 또는 치료용 약학 조성물 | |
CN117323362A (zh) | 一种抗幽门螺杆菌的植物挥发油组合物 | |
US20220016193A1 (en) | ANTIBACTERIAL AND ANTIVIRUS COMPOSITION COMPRISING Extract of CANNABIS SATIVA L. | |
CN101085037A (zh) | 一种兽用中药制剂及其制备方法 | |
AU2019100737A4 (en) | Anti-Helicobacter Pylori Traditional Chinese Medicine composition and applications | |
CN114177232A (zh) | 一种茶叶多酚提取物的提取方法、提取的茶叶多酚提取物及其应用 | |
KR100262072B1 (ko) | 원지로부터 유효성분의 추출·정제방법 및 그 추출물을 함유한생약 조성물 | |
CN1660274A (zh) | 一种治疗奶牛乳房炎的药物组合物及其制备方法 | |
CN114146125B (zh) | 一种抑制口腔感染幽门螺杆菌的中药组合物 | |
CN105770054A (zh) | 用于防治鸡球虫病的药物组合物、添加剂和饲料 | |
WO2004048358A1 (en) | Control of cancer with annonaceous extracts | |
KR101348177B1 (ko) | 패장 추출물을 유효성분으로 함유하는 장출혈성 대장균 감염증의 예방 또는 치료용 약학 조성물 | |
CN103479786B (zh) | 一种用于治疗猪蓝耳病的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |